Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Tatsuhiko Azegami und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2, Drug Prescriptions. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health, Labour and Welfare, Ministry of Education, Culture, Sports, Science and Technology, Japan.
Abstract (Originalsprache)
Aims Chronic kidney disease (CKD) is a growing global health concern, and sodium‐glucose cotransporter 2 (SGLT2) inhibitors have emerged as a key treatment strategy. While their kidney‐protective effects are well established in both genders, women are prescribed these agents less frequently than men for the treatment of type 2 diabetes worldwide. However, data on gender differences in SGLT2 inhibitor prescriptions for CKD remain limited. Materials and Methods This retrospective cohort study examined gender disparities in SGLT2 inhibitor prescriptions among individuals with CKD using a large‐scale real‐world database in Japan. Prescription claims data were extracted from health insurance claims records, and baseline clinical characteristics were obtained from health check‐up records. CKD was defined as an eGFR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
- Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Advanced Cardiology, The University of Tokyo, Tokyo, Japan.
- Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan.
- Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
ORCID-Profile: Hidehiro Kaneko, Koichi Node
Förderung
- Ministry of Health, Labour and Welfare
- Ministry of Education, Culture, Sports, Science and Technology, Japan
Zitieren
APA
Azegami, T., Kaneko, H., Okada, A., Suzuki, Y., Aoyama, K., Nakayama, T., Fujiu, K., Takeda, N., Morita, H., Yokoo, T., Node, K., Nangaku, M., Takeda, N., Yasunaga, H., & Hayashi, K. (2025). Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70020
Vancouver
Azegami T, Kaneko H, Okada A, Suzuki Y, Aoyama K, Nakayama T, et al. Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70020
BibTeX
@article{Azegami2025,
author = {Azegami, Tatsuhiko and Kaneko, Hidehiro and Okada, Akira and Suzuki, Yuta and Aoyama, Kazuki and Nakayama, Takashin and Fujiu, Katsuhito and Takeda, Norifumi and Morita, Hiroyuki and Yokoo, Takashi and Node, Koichi and Nangaku, Masaomi and Takeda, Norihiko and Yasunaga, Hideo and Hayashi, Kaori},
title = {Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70020}
}
EUVIMED